Rigel Pharmaceuticals (RIGL) PT Raised to $7 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Rigel Pharma (RIGL) Prices 16M Share Common Offering at $3.90/Sh
April 20, 2018 5:34 AM EDTRigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public. The gross proceeds to Rigel from this offering are expected to be $62.4 million,... More
Rigel Pharma (RIGL) Announces Proposed 15M Share Common Offering
April 18, 2018 4:36 PM EDTRigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of... More
Rigel Pharmaceuticals (RIGL) PT Raised to $8 at H.C. Wainwright Following FDA Approval
April 18, 2018 7:05 AM EDTH.C. Wainwright raised its price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $8.00 (from $6.70) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, ". Rigel announced yesterday that the FDA approved the NDA for Tavalisse (fostamatinib) for the treatment of adult patients with... More
